Compare NNDM & RGNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NNDM | RGNX |
|---|---|---|
| Founded | 2012 | 2008 |
| Country | United States | United States |
| Employees | 468 | N/A |
| Industry | Electrical Products | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 401.4M | 418.1M |
| IPO Year | 2015 | 2015 |
| Metric | NNDM | RGNX |
|---|---|---|
| Price | $1.91 | $9.35 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $28.75 |
| AVG Volume (30 Days) | ★ 1.8M | 501.4K |
| Earning Date | 05-07-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 18.08 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $102,437,000.00 | $10,393,000.00 |
| Revenue This Year | N/A | $51.21 |
| Revenue Next Year | N/A | $19.08 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | 77.30 | ★ 126.48 |
| 52 Week Low | $1.31 | $6.89 |
| 52 Week High | $2.32 | $16.19 |
| Indicator | NNDM | RGNX |
|---|---|---|
| Relative Strength Index (RSI) | 60.22 | 56.09 |
| Support Level | $1.47 | $7.68 |
| Resistance Level | $2.11 | $9.41 |
| Average True Range (ATR) | 0.09 | 0.47 |
| MACD | 0.01 | 0.02 |
| Stochastic Oscillator | 83.87 | 78.95 |
Nano Dimension Ltd provides industrial manufacturing solutions for the design-to-manufacturing of electronics and mechanical parts. These solutions are based on a combination of hardware, software, and materials science technologies. The solutions include industrial machinery, such as those for additive manufacturing, surface-mount technology, and industrial inkjet printing, along with software for design, simulation, and manufacturing management, as well as materials or consumables that are used by the machinery. These solutions are used by industrial customers in aerospace & defense, automotive, electronics, medical, research, and academia, along with government organizations.
Regenxbio Inc is a clinical-stage biotechnology company focused on the development of gene therapy treatments. Its product candidates are designed to deliver genes to cells to address genetic defects or enable the production of therapeutic proteins. The company is developing a pipeline of investigational gene therapy treatments using its NAV Technology Platform based on adeno-associated virus (AAV) vectors. Its internal research and development programs are focused on therapies for retinal, neuromuscular, and neurodegenerative diseases.